Patents Examined by Quang Nguyen
-
Patent number: 10994027Abstract: Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5? to 3? orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.Type: GrantFiled: February 23, 2017Date of Patent: May 4, 2021Assignee: Provecs Medical GmbHInventors: Frank Schnieders, Andrea Miegel, Carolin Biermann-Fleischhauer
-
Patent number: 10973930Abstract: This document provides methods and materials for generating GABAergic neurons in brains. For example, methods and materials for using nucleic acid encoding a NeuroD1 polypeptide and nucleic acid encoding a Dlx2 polypeptide to trigger glial cells (e.g., NG2 glial cells or astrocytes) within the brain (e.g., striatum) into forming GABAergic neurons (e.g., neurons resembling medium spiny neurons such as DARPP32-positive GABAergic neurons) that are functionally integrated into the brain of a living mammal (e.g., a human) are provided.Type: GrantFiled: February 17, 2017Date of Patent: April 13, 2021Assignee: The Penn State Research FoundationInventors: Gong Chen, Ziyuan Guo, Zheng Wu, Zifei Pei, Yuchen Chen
-
Patent number: 10953109Abstract: The present invention relates to the field of biotechnology, in particular to application of a GPR45 gene. The present invention discloses, for the first time, a correlation between GPR45 and obesity and also discloses that obesity may be caused if the GPR45 gene is knocked out or the expression of the GPR45 gene is reduced. Moreover, an obese mouse model is established by adopting a method of blocking the expression of the GPR45 gene for the first time, which is more similar to the mechanism underlying the obesity of human, is thus an ideal model for obesity basis and clinical application researches and can be well applied in screening of drugs for treating obesity.Type: GrantFiled: May 2, 2019Date of Patent: March 23, 2021Inventors: Xiaohui Wu, Tian Xu, Min Han, Jing Cui, Tongruei Li
-
Patent number: 10906984Abstract: An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells. A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.Type: GrantFiled: May 6, 2019Date of Patent: February 2, 2021Assignee: YAMAGUCHI UNIVERSITYInventors: Koji Tamada, Yukimi Sakoda, Keishi Adachi
-
Patent number: 10889822Abstract: The invention relates to a method for transcription and expression using a nucleic acid construct which is characterized by the presence of a promoter followed by an intronic promoter. The invention further relates to the nucleic acid construct, an expression vector and a cell comprising the construct, and its use. The invention also relates to methods for transcription and optionally expression using a nucleotide sequence. The invention further relates to the nucleotide sequence and a construct, expression vector and cell comprising the nucleotide sequence, and its use.Type: GrantFiled: December 24, 2014Date of Patent: January 12, 2021Inventors: Maurice Wilhelmus van der Heijden, Bart Marinus Engels
-
Patent number: 10865242Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. In some alternatives, the ligand binding domains binds to CD171.Type: GrantFiled: April 8, 2015Date of Patent: December 15, 2020Assignee: Seattle Children's HospitalInventor: Michael C. Jensen
-
Patent number: 10851379Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.Type: GrantFiled: April 25, 2018Date of Patent: December 1, 2020Assignee: BAYER ANIMAL HEALTH GMBHInventors: Marc Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
-
Patent number: 10844388Abstract: A eukaryotic replicative pUC-free minicircle expression vector is provided. The eukaryotic replicative pUC-free minicircle expression vector includes a pUC-free eukaryotic region sequence encoding a transgene of interest and comprising 5? and 3? ends and ii) a pUC-free spacer region of less than 500 basepairs in length linking the 5? and 3? ends of the eukaryotic region sequences and comprising a bacterial R6K replication origin having at least 95% sequence identity to SEQ ID NO: 11 or SEQ ID NO: 12 and a RNA selectable marker, the RNA selectable marker being an RNA-IN regulating RNA-OUT functional variant having at least 95% sequence identity to SEQ ID NO:20 or SEQ ID NO:22.Type: GrantFiled: June 22, 2018Date of Patent: November 24, 2020Assignee: Nature Technology CorporationInventor: James A. Williams
-
Patent number: 10828376Abstract: Described herein are constructs used for liver-specific expression of a transgene.Type: GrantFiled: October 18, 2018Date of Patent: November 10, 2020Assignee: Sangamo Therapeutics, Inc.Inventors: Brigit E. Riley, Gary K. Lee
-
Patent number: 10829785Abstract: Novel forward primer, reverse primer and poly-linker suitable for replication of nucleic acids in e.g., 293 cells.Type: GrantFiled: November 13, 2019Date of Patent: November 10, 2020Assignee: Trizell LimitedInventors: Hanna P. Lesch, Kari J. Airenne, Seppo Yla-Herttuala
-
Patent number: 10767195Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: GrantFiled: October 17, 2019Date of Patent: September 8, 2020Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 10765094Abstract: The present invention provides a method for detection of an inflammatory reaction, which comprises using a transformant or transgenic non-human animal transfected with a vector comprising a promoter for a gene encoding an inflammatory cytokine, a gene encoding a reporter protein, a gene encoding the inflammatory cytokine, and a gene encoding a proteolytic signal sequence to thereby detect an inflammatory reaction induced upon inflammatory stimulation in the transformant or in the transgenic non-human animal.Type: GrantFiled: July 31, 2014Date of Patent: September 8, 2020Assignees: TRANSGENIC INC., NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITYInventors: Kenichi Yamamura, Takao Iwawaki, Daisuke Oikawa, Tomoo Ishikawa
-
Patent number: 10752918Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: GrantFiled: October 18, 2019Date of Patent: August 25, 2020Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 10752917Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: GrantFiled: October 16, 2019Date of Patent: August 25, 2020Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 10752919Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: GrantFiled: October 18, 2019Date of Patent: August 25, 2020Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 10745698Abstract: The invention relates to a polyribonucleotide with a sequence that codes a protein or protein fragment, wherein the polyribonucleotide comprises a combination of unmodified and modified nucleotides, wherein 5 to 50% of the uridine nucleotides and 5 to 50% of the cytidin nucleotides are modified uridine nucleotides or modified cytidin nucleotides.Type: GrantFiled: August 28, 2015Date of Patent: August 18, 2020Assignee: ETHRIS GMBHInventors: Carsten Rudolph, Michael Kormann
-
Patent number: 10729726Abstract: Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. This invention relates to the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, it relates to an adult multipotent cell or a cell population or composition comprising the cell, isolated from non-osteochondral mesenchymal tissue, characterized in that it is positive for the following markers: CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 and because it lacks expression of the following markers: CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 and CD133.Type: GrantFiled: August 24, 2015Date of Patent: August 4, 2020Assignees: TIGENIX, S.A.U., UNIVERSIDAD AUTÓNOMA DE MADRIDInventors: Rosa Ana García Castro, María Gema Fernández Miguel, Mariano García Arranz, Manuel Angel González De La Peña, Damián García Olmo
-
Patent number: 10724053Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.Type: GrantFiled: October 17, 2019Date of Patent: July 28, 2020Assignee: Factor Bioscience Inc.Inventors: Matthew Angel, Christopher Rohde
-
Patent number: 10717976Abstract: Methods and composition for nucleic acid isolation are provided. In one embodiment, a method is provided for nucleic acid purification from biological samples, such as whole blood samples, extracted with phenol-based denaturing solvents, which does not require phase separation or nucleic acid precipitation. Methods according to the invention may also be used for of small RNAs (e.g., siRNAs or miRNAs) purification and are amenable to automation.Type: GrantFiled: December 7, 2015Date of Patent: July 21, 2020Assignee: ZYMO RESEARCH CORPORATIONInventors: Stanislav Forman, Xiyu Jia
-
Patent number: 10709796Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes arc alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.Type: GrantFiled: July 17, 2017Date of Patent: July 14, 2020Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff